NAVANA PHARMA

Navana Pharmaceuticals Ltd.

House # 99, Road # 04, Block-B, Banani, Dhaka-1213, Bangladesh.

Tel: +880-2-550 33580-3, Fax: +880-2-550 33579

E-mail: admin@navanapharma.com

Dividend Compliance Report (2022-2023)

	Dividend Distribution Comp	pliance Report
	Under Clause (6) of the Directive No. BSEC/CMRR	CD/2021-386/03,dated:14/01/2021
1	Name of the Issuer/Securities/Mutual Fund	Navana Pharmaceuticals PLC
2	Particulars of Issuer DP	649
3	Type of the Dividend (Annual/ Interim) (Put tick mark (a) on the recommended option)	a) Annual v b) Interim
4	Whether audited or not for Interim Dividend (Put tick mark (a) on the recommended option)	a) Audited v b) Unaudited
5	Date of recommendation of Dividend by the Board of Directors/Trustee(Enclose Copy of PSI)	22.10.2023
6	Whether Dividend recommended other than directors or sponsors or any other classes (Put tick mark (a) on the recommended option)	a) Yes b) No v
7	Record date for entitlement	19.11.2023
8		a) Cash Dividend: 13%
8	Rate of Dividend recommendation by the Board of Directors/Trustee	b) Bonus/Stock Dividend:
9	Dividend recommended-Type (Put tick mark (a) on the recommended option)	a) Cash v b) Stock
10	Securities/mutual fund traded under which categories (Put tick mark (a) on the recommended option)	a) A v b) B c) G d) N e) Z
11	Date of transfer to a separate bank account (pls. mention bank details) or provisional credit of shares/units by CDBL	A) Date of Cash Dividend Transfer: 15.01.2024, Bank: Al-Arafah Islami Bank PLC, A/C No. 0141220031994, Branch: VIP Road
12	Date of approval of Dividend at AGM	28.12.2023
13	Rate of Dividend approved at AGM-details at Annexure, (in any change)	a) Cash Dividend: 13%
14	Date of commencement of disbursement of Cash and Stock dividend	Disbursed to the respective Bank Accounts of the Shareholders' (who are registered as on Record Date i.e. 19.11.2023) linked with their recorded BO number through BEFTN, EFT & Dividend Warrant from 21.01.2024 to 25.01.2024. The remaining un-remitted cash dividends, due to non-availability of BEFTN facilities or error in information have been dispatched by courier services to the respective shareholders' address registered with the Company on 25.01.2024





Navana Pharmaceuticals Ltd.

House # 99, Road # 04, Block-B, Banani, Dhaka-1213, Bangladesh.

Tel: +880-2-550 33580-3, Fax: +880-2-550 33579

E-mail: admin@navanapharma.com

		* # # #		
		a) BEFTN √	B) Bank Transfe	er 🗸
15	Mode of disbursement of cash dividend			
	(Put tick mark (a) on the recommended option)	C) MFC d) I	Dividend warran	t 🗍
		e) Any other mode 🗸		
	Date of completion of disbursement of cash Dividend and Stock		sh Dividend Transf	
16	Dividend [Enclose Bank statements and Corporate Action		4 to 25.01.2024	
	processing Report (DP70)] Paid-up-capital of the issuer-before corporate	B) Date of Credit of Shares/units by CDBL: N/A		
17	action/entitlement	N/A		
18	Numbers of securities/shares outstanding-before corporate action	n/entitlement:	N/A	
			end TK.139,641	,082.10
19	Total cash in taka or stock (nos. shares) dividend as per	(Included Tax)		
	corporate declaration		k Dividend: N/P	
20	Distribution/disbursement details of Cash & Stock Dividend:	Cash-Net Dividend (Tk.)	Stock (nos.)	Annexures
	A. Mode of Dividend Payment/credit for the concerned			
	year:	- 12		
	a) through BEFTN or directly credited to respective BO	31,277,153.31		Bank Statement
	B) through Bank Transfer other than entitled BO-Margin Loan			David.
	C) through Bank Transfer	1,313,938.05		Bank Statement
	d) through Mobile Financial Service (MFS)			
	e) through any other mode as approved by Bangladesh Bank			
	f) through transfer to Suspense Account for dematerialized Shares (BO wise detailed with reason should be maintained	_		
	and submitted)			
	g) through issuance of Dividend warrant/ Cheque or			-
	issue of Shares to Suspense Account for Non-dematerialized	83,141,751.94		Bank Statement
	securities			
21	Total Dividend paid/credited for the concerned year	115,732,843.30		Bank Statement
22	Total unpaid/undistributed Dividend/accrued during the period	5,335,195.60		
23	Total unpaid/undistributed Dividend/accrued as on 1st day of			
25	Accounting year (as per Audited Accounts) as on 07.07.2023	5,008,375.00	N/P	
24	Transfer to suspense Account for Demate Shares or any other reasons during concerned year	N/P	N/P	
	A. Mode of Dividend Receipts/payment/credit for the previous			
	years:	20 075 244 10	N/P	
	a)through BEFTN directly credited to respective BO	39,975,244.18	N/P N/P	
	b)through Bank Transfer C) through Mobile Financial Service (MFS)	10,801,642.69 N/P	N/P	
	d) through any other mode as approved by Bangladesh Bank	14/1	14/1	
	(Dividend warrant/Cheque)	49,244,747.14	N/P	
	e)through transfer to/from Suspense Account for Demate			
	Shares or any other reasons			
	f)through issuance of Dividend Warrant or issue of shares to			
	Suspense Account for non-dematerialized	N/P	N/P	
	securities/shares/units	1	L.	



Navana Pharmaceuticals Ltd.

House # 99, Road # 04, Block-B, Banani, Dhaka-1213, Bangladesh.

Tel: +880-2-550 33580-3, Fax: +880-2-550 33579

E-mail: admin@navanapharma.com

	g)transfer of cash or stocks to the fund as prescribed or directed by commission after 3 years or forfeit of share to	N/D	N/D	
	Suspense Account for non-dematerialized securities	N/P	N/P	
25	Total Dividend paid/credited for previous years:	N/P	N/P	
26	Total unpaid/undistributed Dividend for previous years		·	
	(23+24-25) Taka/Nos	N/P	N/P	
27	Grand Total of unpaid/undistributed Dividend (22+26)	N/P	N/P	
28	Aging of grand Total of unpaid/undistributed Dividend			
	for previous years:	N/P	N/P	
	More than 3 years; balance	N/P	N/P	
	More than 4 years; balance	N/P	N/P	
	More than 5 years & above ; balance	N/P	N/P	
	Total of unpaid/undistributed Dividend for previous years	N/P	N/P	
	(Supporting bank statement and balances of securities with the Depository)	N/P	N/P	

Note: Issuer shall maintain BO wise details information for all transfers/credit to suspended Accounts

With reasons and submit along with bank statements and other supporting documents. The issuer shall fill up all the applicable fields.

Reporting Date: February 01, 2024

Authorize Signature With seal
(With name & designation)